Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
Molecules · 06.03.2023 · 28 (5) · 2400
DOI: 10.3390/molecules28052400 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 06.03.2023. Verfasst von Dariusz Rozkiewicz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland. Hauptthemen laut MEDLINE: Autoimmune Diseases, Tyrosine Kinase Inhibitors, Neoplasms. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Białystok, Medical University of Białystok, Poland.
Abstract (Originalsprache)
In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and differentiation. Evidence demonstrating the expression of BTK on the majority of hematological cells has led to the hypothesis that BTK inhibitors (BTKIs) such as ibrutinib can be an effective treatment for leukemias and lymphomas. However, a growing body of experimental and clinical data has demonstrated the significance of BTK, not just in B-cell malignancies, but also in solid tumors, such as breast, ovarian, colorectal, and prostate cancers. In addition, enhanced BTK activity is correlated with autoimmune disease. This gave rise to the hypothesis that BTK inhibitors can be beneficial in the therapy of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS), Sjögren’s syndrome (SS), allergies, and asthma. In this review article, we summarize the most recent findings regarding this kinase as well as the most advanced BTK inhibitors that have been developed to date and their clinical applications mainly in cancer and chronic inflammatory disease patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland.
- Department of Clinical Pharmacy, Medical University of Bialystok, Mickiewicza 2c, 15-222 Bialystok, Poland.
- Department of Internal Medicine and Metabolic, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland.
ORCID-Profile: Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Dariusz Pawlak
Förderung
- Medical University of Białystok
- Medical University of Białystok, Poland
Zitieren
APA
Rozkiewicz, D., Hermanowicz, J. M., Kwiatkowska, I., Krupa, A., & Pawlak, D. (2023). Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. Molecules, 28(5), 2400. https://doi.org/10.3390/molecules28052400
Vancouver
Rozkiewicz D, Hermanowicz JM, Kwiatkowska I, Krupa A, Pawlak D. Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. Molecules. 2023;28(5):2400. doi:10.3390/molecules28052400
BibTeX
@article{Rozkiewicz2023,
author = {Rozkiewicz, Dariusz and Hermanowicz, Justyna Magdalena and Kwiatkowska, Iwona and Krupa, Anna and Pawlak, Dariusz},
title = {Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials},
journal = {Molecules},
year = {2023},
volume = {28},
number = {5},
pages = {2400},
doi = {10.3390/molecules28052400}
}
EUVIMED